RxDoctor Payments Data

Manuel Rivera, MD

Cardiovascular Disease · Arecibo, PRNPI 1659356954

Payments from drug & device makers

$976in general payments, 2019–2025

Across 35 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • PBG Puerto Rico LLC$364
  • Cardiovascular Systems Inc.$282
  • Medtronic$188
  • E.r. Squibb & Sons, L.L.C.$85
  • AstraZeneca$44
  • Pfizer Pharmaceuticals LLC$13

What the payments were for

  • Food & beverage$976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
PBG Puerto Rico LLC19$364
Cardiovascular Systems Inc.4$282
Medtronic2$188
E.r. Squibb & Sons, L.L.C.6$85
AstraZeneca3$44
Pfizer Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$976 in reported general payments places this provider in the 25th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,365
Medicare patients
20
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$124,124
FarxigaDapagliflozin Propanediol93$100,074
JanuviaSitagliptin Phosphate77$66,659
Janumet XrSitagliptin Phos/Metformin Hcl34$40,843
XareltoRivaroxaban35$23,037
EntrestoSacubitril/Valsartan19$18,613
JardianceEmpagliflozin18$18,244
SynthroidLevothyroxine Sodium155$18,047
OzempicSemaglutide13$16,642
Candesartan Cilexetil94$12,095
Metoprolol Succinate652$11,191
LantusInsulin Glargine,hum.Rec.Anlog56$8,937
Rosuvastatin Calcium575$8,453
Atorvastatin Calcium663$7,196
Losartan Potassium514$6,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$44$102,799105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →